US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More
Financial, Psychological Burden of Abortion Care in US Raises Calls for Expanded Insurance
November 13th 2024There are significant financial and psychological burdens of abortion care in the US, especially for those traveling out of state due to local restrictions in the increasingly restrictive post-Dobbs landscape.
Read More
New Research Suggest Benefits of Telehealth BCBT for Treating Suicidal Thoughts, Mitigating Attempts
November 12th 2024Researchers evaluated the lesser-known impact of telehealth treatments, including brief cognitive behavioral therapy (BCBT), to address the needs of individuals at risk of or recovering from suicidal ideation.
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Addressing Psychosocial Needs and Navigating Financial Toxicity Shared the Spotlight at ACCC
October 15th 2024Financial toxicity and patient and staff wellness were well explored at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference, serving as the focal point of multiple posters and presentations.
Read More
Expansion of Certified Community Behavioral Health Clinics Increases Access to Mental Health
October 4th 2024The extent to which certified community behavioral health clinic expansion reaches different parts of the country remained unclear until this study, which measured the proportion of US counties and populations within the service areas.
Read More
Finding Strength Together: Peer Support in Recovery
September 20th 2024This interview accompanies the third podcast in our National Recovery Month series with Kim MacDonald-Wilson, ScD, CPRP, senior program director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery and resiliency specialist, Community Care Behavioral Health Organization.
Read More
Recovery Through Compassionate Care for Substance Use Disorder
September 12th 2024This interview accompanies the second podcast in our National Recovery Month series with Mandy Faubel, PhD, LCSW, UPMC Western Behavioral Health at Safe Harbor, and Rebekah Sedlock, DSW, LCSW, UPMC Insurance Services Division with Community Care.
Read More
Biden-Harris Administration Expands Mental Health Coverage Protections Nationwide
September 10th 2024Ali Khawar, Employee Benefits Security Administration, US Department of Labor, believes the final rule will be a benefit to employers and health plans that are trying to do the right thing and offer robust mental health benefits or substance use benefits.
Read More
Health Equity & Access Weekly Roundup: August 24, 2024
August 24th 2024Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.
Read More
Following FDA Rejection, Experts Discuss MDMA Therapy, Improving Care for Veterans With PTSD
August 21st 2024The FDA's decision to reject midomafetamine (MDMA) capsules in combination with assisted psychotherapy (MDMA-AT) for adults with PTSD reignited the controversial conversation around investigative psychedelic therapy.
Read More
Lykos Therapeutics Restructures After FDA Setback, Commits to Progressing MDMA Therapy for PTSD
August 16th 2024Along with the company reorganization, Lykos announced it will be reducing its workforce by approximately 75%, with the remaining team focused on continuing efforts in clinical development, medical affairs, and engagement with the FDA.
Read More
Bipartisan Letter to President Biden Highlights Promise of MDMA Therapy for PTSD
August 7th 2024Over 60 bipartisan members of Congress wrote a letter to President Joe Biden stating the urgent need to address the suicide epidemic among veterans, advocating for innovative treatments like therapeutic MDMA.
Read More
Telehealth Availability for Mental Health Care Declined After COVID-19 Public Health Emergency
July 31st 2024Researchers analyzed the availability of telehealth services at mental health treatment facilities across the US before and after the end of the COVID-19 public health emergency through a national secret shopper analysis.
Read More
Roughly 7% of US women of reproductive age have attempted self-induced abortions after the overturning of Roe v Wade in 2022; the FDA announced that the cost to file a drug using clinical data will increase to about $4.3 million in 2025; the suicide rate among US children aged between 8 to 12 years has steadily risen during the past 15 years.
Read More